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Background
Acute myeloid leukemia (AML) is a clonal hematopoietic
disorder characterized by enhanced proliferation and
block in differentiation of immature myeloid cells. AML
pathogenesis is attributed to several recurrent chromoso-
mal abnormalities in nearly half of the AML cases while
the rest of the AML cases show at least one or more mole-
cular abnormalities. Activating mutations and/or high
expression of receptor tyrosine kinase (RTK) family mem-
bers (FLT3, cKIT) have been well documented in AML.
Specific RTK inhibitors (TKI) have been developed for tar-
geted therapy of AML and many are currently under study
[1]. Sunitinib is a potent multi-TKI that has been FDA
approved for renal carcinoma and imatinib resistant gastro
intestinal tumors. Although some studies show the effect
of Sunitinib on AML cell line growth, there has been no
investigation of its effect on AML clonogenic cells [2]. In
the current study, we investigated the effect of Sunitinib
on clonogenic AML cells and normal hematopoietic pro-
genitors in vitro.
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Figure 1 Inhibition of AML-CFC (n=4) and normal CD34+ -cell derived CFC with Sunitinib.
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Materials and methods
Human primary AML patient bone marrow or peripheral
blood mononuclear cells (AML-MNC) were isolated by
density gradient centrifugation. Human normal hemato-
poietic stem/progenitors cells (HSPC) were isolated from
umbilical cord blood using anti-CD34 antibodies on a
magnetic separator (Miltenyi Biotech). AML-MNCs and
HSPC were incubated in SFEM (Stem Cell Technologies)
with varying concentrations of Sunitinib malate (Sigma)
and DMSO as vehicle control for 24 hours. Clonogenic
assays were performed by plating the drug treated cells in
Methycellulose and the colonies were evaluated after 10-
14 days. CD34+ ALDH+ cells were stained using Aldefluor
Kit (Stem Cell Technologies) and CD34-VioBlue antibo-
dies (Miltenyi Biotech).
Results
With 7µM Sunitinib, there was a 75% reduction (±6.79%;
n=4) of AML-CFC as compared to untreated, while 70µM
Sunitinib treatment showed total eradication of AML-
CFC. Treatment of normal HSPC with 7µM Sunitinib
showed only 29% reduction (±6.77%; n=5) (Figure 1) of
normal CFC. In two additional AML cases, CD34+ALDH
+cells and CD34- ALDH- cells were sorted and incubated
with or without Sunitinib. AML colonies were detected
only in CD34+ALDH+ population that showed total inhibi-
tion by 7 µM Sunitinib.
Conclusions
Sunitinib is effective in reduction of clonogenic AML cells.
Sunitinib also inhibits normal HSPC derived CFCs albeit
less effectively than AML-CFC. This study highlights the
relevance of TKI inhibitors in targeting AML. Further stu-
dies are aimed at confirming the molecular mechanisms
involved in the inhibition as well as taking this study
further for targeting patient derived leukemic stem cells
using immuno-deficient mouse models.
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